Definitive dose thoracic radiation therapy in oligometastatic non-small cell lung cancer: A hypothesis-generating study

Practical Radiation Oncology

Volumn 5, Issue 4, 2015, Pages e355-e363

  Xanthopoulos, Eric P ^a,b   Handorf, Elizabeth ^b,d   Simone, Charles B ^a   Grover, Surbhi ^a   Fernandes, Annemarie T ^a   Sharma, Sonam ^a   Corradetti, Michael N ^a,e   Evans, Tracey L ^c   Langer, Corey J ^c   Mitra, Nandita ^c   Shah, Anand ^a,b   Apisarnthanarax, Smith ^a   Lin, Lilie L ^a   Rengan, Ramesh ^a,f  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NewYork Presbyterian Hospital   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d Fox Chase Center   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; ESOPHAGITIS; FEMALE; HUMAN; LUNG METASTASIS; MALE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; SEX DIFFERENCE; TREATMENT FAILURE; CARCINOMA, NON-SMALL-CELL LUNG; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MORTALITY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84937162986     PISSN: 18798500     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prro.2014.11.006     Document Type: Article

References (27)

1. Socinski M.A., Crowell R., Hensing T.E., et al. American College of Chest Physicians. Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132(3 Suppl.):277S-289S.
2. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer [published correction appears in N Engl J Med. 2007;356:318]. N Engl J Med 2006, 355(24):2542-2550.
3. Thatcher N., Ranson M., Lee S.M., Niven R., Anderson H. Chemotherapy in non-small cell lung cancer. Ann Oncol 1995, 6(Suppl. 1):83-94.
4. Scagliotti G.V., Parikh P., von Pawel J., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26(21):3543-3551.
5. Azzoli C.G., Baker S., Temin S., et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009, 27(36):6251-6266.
6. Rodrigues G., Videtic G.M., Sur R., et al. Palliative thoracic radiotherapy in lung cancer: An American Society for Radiation Oncology evidence-based clinical practice guideline. Pract Radiat Oncol 2011, 1:60-71.
7. Lester J.F., Macbeth F.R., Toy E., Coles B. Palliative radiotherapy regimens for non-small cell lung cancer. Cochrane Database Syst Rev 2006, 4:CD002143.
8. Gray P.J., Mak R.H., Yeap B.Y., et al. Aggressive therapy for patients with non-small cell lung carcinoma and synchronous brain-only oligometastatic disease is associated with long-term survival. Lung Cancer 2014, 85(2):239-244.
9. Ashworth A.B., Senan S., Palma D.A., et al. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. Clin Lung Cancer 2014, 15(5):346-355.
10. Griffioen G.H., Toguri D., Dahele M., et al. Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): Patient outcomes and prognostic factors. Lung Cancer 2013, 82(1):95-102.
11. Jabbour S.K., Daroui P., Moore D., Licitra E., Gabel M., Aisner J. A novel paradigm in the treatment of oligometastatic non-small cell lung cancer. J Thorac Dis 2011, 3(1):4-9.
12. Cox J.D., Stetz J., Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995, 31(5):1341-1346.
13. Marks L.B., Bentzen S.M., Deasy J.O., et al. Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys 2010, 76(3 Suppl.):S70-S76.
14. Rosenzweig K.E., Fox J.L., Yorke E., et al. Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma. Cancer 2005, 103(10):2118-2127.
15. Eisenhauer E.A., Therasse P., Bogaerts J., et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45(2):228-247.
16. Abbasi S., Badheeb A. Prognostic factors in advanced non-small-cell lung cancer patients: Patient characteristics and type of chemotherapy. Lung Cancer Int 2011, Accessed January 12, 2015. 10.4061/2011/152125.
17. Albain K.S., Crowley J.J., LeBlanc M., Livingston R.B. Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience. J Clin Oncol 1991, 9(9):1618-1626.
18. Rodrigues G., Eppinga W., Lagerwaard F., et al. A pooled analysis of arc-based image-guided simultaneous integrated boost radiation therapy for oligometastatic brain metastases. Radiother Oncol 2012, 102(2):180-186.
19. Takeda A., Kunieda E., Ohashi T., Aoki Y., Koike N., Takeda T. Stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer and other primary cancers in comparison with primary lung cancer. Radiother Oncol 2011, 101(2):255-259.
20. Sheu T., Heymach J.V., Swisher S.G., et al. Propensity score-matched analysis of comprehensive local therapy for oligometastatic non-small cell lung cancer that did not progress after front-line chemotherapy. Int J Radiat Oncol Biol Phys 2014, 90(4):850-857.
21. Khan A.J., Mehta P.S., Zusag T.W., et al. Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC). Radiother Oncol 2006, 81(2):163-167.
22. Hasselle M.D., Haraf D.J., Rusthoven K.E., et al. Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. J Thorac Oncol 2012, 7:376-381.
23. Cheruvu P., Metcalfe S.K., Metcalfe J., Chen Y., Okunieff P., Milano M.T. Comparison of outcomes in patients with stage III versus limited stage IV non-small cell lung cancer. Radiat Oncol 2011, 30:80.
24. De Ruysscher D., Wanders R., van Baardwijk A., et al. Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: Long-term results of a prospective phase II trial (Nct01282450). J Thorac Oncol 2012, 7:1547-1555.
25. Parikh R.B., Cronin A.M., Kozono D.E., et al. Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2014, 89(4):880-887.
26. Lopez Guerra J.L., Gomez D., Zhuang Y., et al. Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis. Int J Radiat Oncol Biol Phys 2012, 84(1):e61-e67.
27. Schild S.E., Henning G.T., Garces Y.I., Adjei A.A., Stella P.J. Randomized phase II study of oligometastatic stage IV non-small cell lung cancer (NSCLC) treated with systemic therapy plus either radiotherapy to all sites of gross residual disease or no radiotherapy: NCCTG status report for study N0724 Available at:, Accessed January 12, 2015. http://ncctg.mayo.edu/thebook/Books/Spring_2010/N0724.pdf.